Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis

Science Translational Medicine

Volumn 4, Issue 135, 2012, Pages

  Sergeev, Rinat ^a,b   Colijn, Caroline ^c   Murray, Megan ^a,d   Cohen, Ted ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IOFFE INSTITUTE   (Russian Federation)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CASE FINDING; CD4 LYMPHOCYTE COUNT; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LATENT TUBERCULOSIS; MATHEMATICAL MODEL; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; DRUG EFFECT; HUMAN; PATHOGENICITY; THEORETICAL MODEL;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861474432     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003815     Document Type: Article

References (115)

1. World Health Organization, Global Tuberculosis Control 2011 (World Health Organization, Geneva, 2011).
2. S. D. Lawn, G. Churchyard, Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4, 325-333 (2009).
3. H. Getahun, C. Gunneberg, R. Granich, P. Nunn, HIV infection-associated tuberculosis: The epidemiology and the response. Clin. Infect. Dis. 50, S201-S207 (2010).
4. C. D. Wells, J. P. Cegielski, L. J. Nelson, K. F. Laserson, T. H. Holtz, A. Finlay, K. G. Castro, K. Weyer, HIV infection and multidrug-resistant tuberculosis - The perfect storm. J. Infect. Dis. 196, S86-S107 (2007).
5. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB), WHO Global Report on Surveillance and Response (World Health Organization, Geneva, 2010).
6. R. C. Chaisson, G. Slutkin, Tuberculosis and human immunodeficiency virus infection. J. Infect. Dis. 159, 96-100 (1989).
7. A. D. Harries, C. Dye, Tuberculosis. Ann. Trop. Med. Parasitol. 100, 415-431 (2006).
8. S. D. Lawn, L. G. Bekker, K. Middelkoop, L. Myer, R. Wood, Impact of HIV Infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: The need for age-specific interventions. Clin. Infect. Dis. 42, 1040-1047 (2006).
9. J. R. Glynn, J. Murray, A. Bester, G. Nelson, S. Shearer, P. Sonnenberg, Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 22, 1859-1867 (2008).
10. N. S. Shah, A. Wright, G. H. Bai, L. Barrera, F. Boulahbal, N. Martin-Casabona, F. Drobniewski, C. Gilpin,M. Havelkova, R. Lepe, R. Lumb, B. Metchock, F. Portaels, M. F. Rodrigues, S. Rusch-Gerdes, A. van Deun, V. Vincent, K. Laserson, C. Wells, J. P. Cegielski, Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 380-387 (2007).
11. N. R. Gandhi, A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, G. Friedland, Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
12. M. C. Raviglione, Facing extensively drug-resistant tuberculosis - A hope and a challenge. N. Engl. J. Med. 359, 636-638 (2008).
13. J. V. Lazarus, M. Olsen, L. Ditiu, S. Matic, Tuberculosis-HIV co-infection: Policy and epidemiology in 25 countries in the WHO European region. HIV Med. 9, 406-414 (2008).
14. M. Murray, T. Cohen, Extensively drug-resistant tuberculosis and HIV/AIDS, in AIDS and Tuberculosis: A Deadly Liaison, S. H. E. Kaufmann, B. D. Walker, Eds. (Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2009).
15. M. A. Espinal, E. N. Peréz, J. Baéz, L. Hénriquez, K. Fernández, M. Lopez, P. Olivo, A. L. Reingold, Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: A prospective study. Lancet 355, 275-280 (2000).
16. R. Wood, K. Middelkoop, L. Myer, A. D. Grant, A. Whitelaw, S. D. Lawn, G. Kaplan, R. Huebner, J. McIntyre, L. G. Bekker, Undiagnosed tuberculosis in a community with high HIV prevalence: Implications for tuberculosis control. Am. J. Respir. Crit. Care Med. 175, 87-93 (2007).
17. E. L. Corbett, T. Bandason, Y. B. Cheung, S. Munyati, P. Godfrey-Faussett, R. Hayes, G. Churchyard, A. Butterworth, P. Mason, Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 4, e22 (2007).
18. C. Dye, B. G. Williams, M. A. Espinal, M. C. Raviglione, Erasing the World's slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 295, 2042-2046 (2002).
19. S. Suchindran, E. S. Brouwer, A. van Rie, Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 4, e5561 (2009).
20. E. Sanchez-Padilla, T. Dlamini, A. Ascorra, S. Rusch-Gerdes, Z. D. Tefera, P. Calain, R. de la Tour, F. Jochims, E. Richter, M. Bonnet, High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010. Emerg. Infect. Dis. 18, 29-37 (2012).
21. S. M. Blower, H. Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int. Stat. Rev. 62, 229-243 (1994).
22. Tuberculosis Country Profiles, WHO's Global TB Database (World Health Organization, Geneva, 2011); http://www.who.int/tb/country/data/profiles/en/ index.html.
23. E. L. Corbett, C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, C. Dye, The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021 (2003).
24. T. Cohen, M. Murray, Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 10, 1117-1121 (2004).
25. O. J. Strauss, R. M. Warren, A. Jordaan, E. M. Streicher, M. Hanekom, A. A. Falmer, H. Albert, A. Trollip, E. Hoosain, P. D. van Helden, T. C. Victor, Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 46, 1514-1516 (2008).
26. P. Bifani, B. Mathema, N. Kurepina, E. Shashkina, J. Bertout, A. S. Blanchis, S. Moghazeh, J. Driscoll, B. Gicquel, R. Frothingham, B. N. Kreiswirth, The evolution of drug resistance in Mycobacterium tuberculosis: From amono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. J. Infect. Dis. 198, 90-94 (2008).
27. B. G. Williams, E. L. Korenromp, E. Gouws, G. P. Schmid, B. Auvert, C. Dye, HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J. Infect. Dis. 194, 1450-1458 (2006).
28. S. D. Lawn, A. D. Harries, B. G. Williams, R. E. Chaisson, E. Losina, K. M. De Cock, R. Wood, Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int. J. Tuberc. Lung Dis. 15, 571-581 (2011).
29. E. L. Corbett, S. Charalambous, V. M. Moloi, K. Fielding, A. D. Grant, C. Dye, K. M. De Cock, R. J. Hayes, B. G. Williams, G. J. Churchyard, Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am. J. Respir. Crit. Care Med. 170, 673-679 (2004).
30. S. M. Blower, T. Chou, Modeling the emergence of the 'hot zones': Tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 10, 1111-1116 (2004).
31. C. Colijn, T. Cohen, M. Murray, Latent coinfection and the maintenance of strain diversity. Bull. Math. Biol. 71, 247-263 (2009).
32. R. Sergeev, C. Colijn, T. Cohen, Models to understand the population-level impact of mixed strain M. tuberculosis infections. J. Theor. Biol. 280, 88-100 (2011).
33. M. F. Boni, M. W. Feldman, Evolution of antibiotic resistance by human and bacterial niche construction. Evolution 59, 477-491 (2005).
34. R. A. Atun, R. Lebcir, F. Drobniewski, R. J. Coker, Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: System dynamics simulation model. Int. J. STD AIDS 16, 560-570 (2005).
35. S. Basu, J. R. Andrews, E. M. Poolman, N. R. Gandhi, N. S. Shah, A. Moll, P. Moodley, A. P. Galvani, G. H. Friedland, Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: An epidemiological modelling study. Lancet 370, 1500-1507 (2007).
36. O. Sharomi, C. N. Podder, A. B. Gumel, B. Song, Mathematical analysis of the transmission dynamics of HIV/TB coinfection in the presence of treatment. Math. Biosci. Eng. 5, 145-174 (2008).
37. D. W. Dowdy, R. E. Chaisson, G. Maartens, E. L. Corbett, S. E. Dorman, Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. Proc. Natl. Acad. Sci. U.S.A. 105, 11293-11298 (2008).
38. S. Basu, A. P. Galvani, The transmission and control of XDR TB in South Africa: An operations research and mathematical modelling approach. Epidemiol. Infect. 136, 1585-1598 (2008).
39. C. Dye, M. A. Espinal, Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268, 45-52 (2001).
40. F. Luciani, S. A. Sisson, H. Jiang, A. R. Francis, M. M. Tanaka, The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 106, 14711-14715 (2009).
41. P. Schulz zur Wiesch, J. Engelstadter, S. Bonhoeffer, Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob. Agents Chemother. 54, 2085-2095 (2010).
42. S. Borell, S. Gagneux, Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 17, 815-820 (2011).
43. B. Wallace, Can "stepping stones" form stairways? Am. Nat. 133, 578-579 (1989).
44. B. R. Edlin, J. I. Tokars, M. H. Grieco, J. T. Crawford, J. Williams, E. M. Sordillo, K. R. Ong, J. O. Kilburn, S. W. Dooley, K. G. Castro, W. R. Jarvis, S. D. Holmberg, An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326, 1514-1521 (1992).
45. A. Guerrero, J. Cobo, J. Fortún, E. Navas, C. Quereda, A. Asensio, J. Cañón, J. Blazquez, E. Gómez-Mampaso, Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 350, 1738-1742 (1997).
46. M. M. Braun, J. O. Kilburn, R. W. Smithwick, I. M. Coulibaly, D. Coulibaly, V. A. Silcox, E. Gnaore, G. Adjorlolo, K. M. de Cock, HIV infection and primary resistance to antituberculosis drugs in Abidjan, Côte d'Ivoire. AIDS 6, 1327-1330 (1992).
47. H. J. Chum, R. J. O'Brien, T. M. Chonde, P. Graf, H. L. Rieder, An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 10, 299-309 (1996).
48. D. Anastasis, G. Pillai, V. Rambiritch, S. S. Abdool Karim, A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. Int. J. Tuberc. Lung Dis. 1, 220-224 (1997).
49. F. A. Post, R. Wood, HIV infection is not associated with an increased rate of drug-resistant tuberculosis. S. Afr. Med. J. 87, 903 (1997).
50. J. Murray, P. Sonnenberg, S. Shearer, P. Godfrey-Faussett, Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S. Afr. Med. J. 90, 381-386 (2000).
51. A. Mac-Arthur, S. Gloyd, P. Perdigao, A. Noya, J. Sacarlal, J. Kreiss, Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int. J. Tuberc. Lung Dis. 5, 894-902 (2001).
52. K. Weyer, J. Brand, J. Lancaster, J. Levin, M. van der Walt, Determinants of multidrug-resistant tuberculosis in South Africa: Results from a national survey. S. Afr. Med. J. 97, 1120-1128 (2007).
53. Anti-Tuberculosis Drug Resistance in the World, WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (World Health Organization, Geneva, 2008).
54. I. Morozova, V. Riekstina, G. Sture, C. Wells, V. Leimane, Impact of the growing HIV-1 epidemic on multidrug-resistant tuberculosis control in Latvia. Int. J. Tuberc. Lung Dis. 7, 903-906 (2003).
55. I. Dubrovina, K. Miskinis, S. Lyepshina, Y. Yann, H. Hoffmann, R. Zaleskis, P. Nunn, M. Zignol, Drug-resistant tuberculosis and HIV in Ukraine: A threatening convergence of two epidemics? Int. J. Tuberc. Lung Dis. 12, 756-762 (2008).
56. G. E. Louw, R. M. Warren, N. C. Gey van Pittius, R. Leon, A. Jimenez, R. Hernandez-Pando, C. R. E. McEvoy, M. Grobbelaar, M. Murray, P. D. van Helden, T. C. Victor, Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184, 269-276 (2011).
57. K. N. Adams, K. Takaki, L. E. Connolly, H. Wiedenhoft, K. Winglee, O. Humbert, P. H. Edelstein, C. L. Cosma, L. Ramakrishnan, Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145, 39-53 (2011).
58. C. Dye, B. G. Williams, Slow elimination of multidrug-resistant tuberculosis. Sci. Transl. Med. 1, 3ra8 (2009).
59. S. Gagneux, Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 15, 66-68 (2009).
60. O. S. Toungoussova, D. A. Caugant, P. Sandven, A. O. Mariandyshev, G. Bjune, Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol. Med. Microbiol. 42, 281-290 (2004).
61. I. Parwati, R. van Crevel, D. van Soolingen, Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 10, 103-111 (2010).
62. E. Vynnycky, P. E. Fine, The natural history of tuberculosis: The implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183-201 (1997).
63. I. Sutherland, E. Svandová, S. Radhakrishna, The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63, 255-268 (1982).
64. E. Brooks-Pollock, M. C. Becerra, E. Goldstein, T. Cohen, M. B. Murray, Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru. J. Infect. Dis. 203, 1582-1589 (2011).
65. J. A. Myers, The natural history of tuberculosis in the human body; forty-five years of observation. JAMA 194, 1086-1092 (1965).
66. C. S. Currie, B. G. Williams, R. C. Cheng, C. Dye, Tuberculosis epidemics driven by HIV: Is prevention better than cure? AIDS 17, 2501-2508 (2003).
67. V. Kawai, G. Soto, R. H. Gilman, C. T. Bautista, L. Caviedes, L. Huaroto, E. Ticona, J. Ortiz, M. Tovar, V. Chavez, R. Rodriguez, A. R. Escombe, C. A. Evans, Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am. J. Trop. Med. Hyg. 75, 1027-1033 (2006).
68. K. P. Cain, N. Kanara, K. F. Laserson, C. Vannarith, K. Sameourn, K. Samnang, M. L. Qualls, C. D. Wells, J. K. Varma, The epidemiology of HIV-associated tuberculosis in rural Cambodia. Int. J. Tuberc. Lung Dis. 11, 1008-1013 (2007).
69. D. Moore, C. Liechty, P. Ekwarua, W. Were, G. Mwima, P. Solberg, G. Rutherford, J. Mermin, Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21, 713-719 (2007).
70. J. E. Golub, B. Durovni, B. S. King, S. C. Cavalacante, A. G. Pacheco, L. H. Moulton, R. D. Moore, R. E. Chaisson, V. Saraceni, Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 22, 2527-2533 (2008).
71. Estimation and Projection Package 2009 (UNAIDS manual for generalized epidemics, Joint United Nations Programme on HIV/AIDS, 2009); http://www.unaids.org/en/dataanalysis/tools/epp2009/.
72. T. Cohen, B. Sommers, M. Murray, The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13-21 (2003).
73. D. I. Andersson, The biological cost of mutational antibiotic resistance: Any practical conclusions? Curr. Opin. Microbiol. 9, 461-465 (2006).
74. S. Gagneux, C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, B. J. M. Bohannan, The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944-1946 (2006).
75. Y. S. Kang, W. Park, Trade-off between antibiotic resistance and biological fitness in Acinetobacter sp. strain DR1. Environ. Microbiol. 12, 1304-1318 (2010).
76. M. G. Reynolds, Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156, 1471-1481 (2000).
77. S. H. Gillespie, O. J. Billington, A. Breathnach, T. D. McHugh, Multiple drug-resistant Mycobacterium tuberculosis: Evidence for changing fitness following passage through human hosts. Microb. Drug Resist. 8, 273-279 (2002).
78. S. Borrell, S. Gagneux, Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13, 1456-1466 (2009).
79. W. Lew, M. Pai, O. Oxlade, D. Martin, D. Menzies, Initial drug resistance and tuberculosis treatment outcomes: Systematic review and meta-analysis. Ann. Intern. Med. 149, 123-134 (2008).
80. Mathematica 8.0.1.0 for Mac OSX x86, Wolfram Research Inc.
81. S. Allen, J. Batungwanayo, K. Kerlikowske, A. R. Lifson, W. Wolf, R. Granich, H. Taelman, P. Van de Perre, A. Serufilira, J. Bogaerts, G. Slutkin, P. C. Hopewell, Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am. Rev. Respir. Dis. 146, 1439-1444 (1992).
82. D. W. Mulder, A. J. Nunn, A. Kamali, J. Nakiyingi, H. U. Wagner, J. F. Kengeya-Kayondo, Two-year HIV-1-associated mortality in a Ugandan rural population. Lancet 343, 1021-1023 (1994).
83. A. Pablos-Méndez, T. R. Sterling, T. R. Frieden, The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 276, 1223-1228 (1996).
84. H. E. Hilleboe, Post-sanatorium tuberculosis survival rates in Minnesota. Pub. Health Rep. 56, 895-907 (1941).
85. G. Berg, The prognosis of open pulmonary tuberculosis. A clinical statistical analysis. Acta Tuber. Scand. 4, 1-207 (1939).
86. G. Drolet, Present trend of case fatality rates in tuberculosis. Am. Rev. Tuberc. 37, 125-151 (1938).
87. V. H. Springett, Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle 52, 73-87 (1971).
88. C. R. Lowe, Recent trends in survival of patients with respiratory tuberculosis. Br. J. Prev. Soc. Med. 8, 91-98 (1954).
89. Tuberculosis in a rural population of South India: A five-year epidemiological study. Bull. World Health Organ. 51, 473-488 (1974).
90. B. C. Thompson, Survival rates in pulmonary tuberculosis. Br. Med. J. 2, 721 (1943).
91. P. M. Small, G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, P. C. Hopewell, Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 324, 289-294 (1991).
92. F. Palmieri, A. M. Pellicelli, E. Girardi, A. P. de Felici, P. de Mori, N. Petrosillo, G. Ippolito, Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. Infection 27, 331-334 (1999).
93. P. Nunn, R. Brindle, L. Carpenter, J. Odhiambo, K. Wasunna, R. Newnham, W. Githui, S. Gathua, M. Omwega, K. McAdam, Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am. Rev. Respir. Dis. 146, 849-854 (1992).
94. J. H. Perriëns, M. E. St Louis, Y. B. Mukadi, C. Brown, J. Prignot, F. Pouthier, F. Portaels, J. C. Willame, J. K. Mandala, M. Kaboto, R. W. Ryder, G. Roscigno, P. Piot, Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N. Engl. J. Med. 332, 779-784 (1995).
95. J. A. Rutledge, J. B. Crouch, The ultimate results in 1694 cases of tuberculosis treated at the Modern Woodmen Sanitorium of America. Am. Rev. Tuberc. 2, 755-756 (1919).
96. W. H. Tattersall, The survival of sputum-positive consumptives; a study of 1,192 cases in a county borough between 1914 and 1940. Tubercle 28, 85 (1947).
97. T. Madsen, J. Holm, K. A. Jensen, Studies on the epidemiology of tuberculosis in Denmark. Acta Tuber. Scand. 6, 1-176 (1942).
98. S. Bergqvist, T. Ernberg, Zur Frage der tuberkulosen Primarinfektion bei jungen Erwachsenen. Acta Med. Scand. 115, 57-82 (1943).
99. C. L. Daley, P. M. Small, G. F. Schecter, G. K. Schoolnik, R. A. McAdam, W. R. Jacobs Jr., P. C. Hopewell, An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N. Engl. J. Med. 326, 231-235 (1992).
100. G. Di Perri, M. C. Danzi, G. De Checchi, S. Pizzighella, M. Solbiati, D. Bassetti, M. Cruciani, R. Luzzati, M. Malena, R. Mazzi, E. Concia, Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 2, 1502-1504 (1989).
101. P. Nunn, M. Mungai, J. Nyamwaya, C. Gicheha, R. J. Brindle, D. T. Dunn, W. Githui, J. O. Were, K. P. McAdam, The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuber. Lung Dis. 75, 25-32 (1994).
102. G. D. Barnett, S. Grzybowski, K. Styblo, The current risk of contracting evolutive tuberculosis, in Saskatchewan, according to the state of previous tuberculin tests and x-ray image. Bull. Int. Union Tuberc. 45, 55-79 (1971).
103. G. W. Comstock, V. T. Livesay, S. F. Woolpert, The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 99, 131-138 (1974).
104. K. Styblo, Epidemiology of tuberculosis. R. Netherlands Tuberc. Assoc. 24, 1 (1991).
105. C. B. Holmes, R. Wood, M. Badri, S. Zilber, B. Wang, G. Maartens, H. Zheng, Z. Lu, K. A. Freedberg, E. Losina, CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment. J. Acquir. Immune Defic. Syndr. 42, 464-469 (2006).
106. C. F. Gilks, P. Godfrey-Faussett, B. I. F. Batchelor, J. C. Ojoo, S. J. Ojoo, R. J. Brindle, J. Paul, J. Kimari, M. C. Bruce, J. Bwayo, F. A. Plummer, D. A. Warrell, Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. AIDS 11, 911-918 (1997).
107. J. R. Glynn, Resurgence of tuberculosis and the impact of HIV infection. Br. Med. Bull. 54, 579-593 (1998).
108. P. A. Selwyn, D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, G. H. Friedland, A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320, 545-550 (1989).
109. C. Dye, B. G. Williams, Eliminating human tuberculosis in the twenty-first century. J. R. Soc. Interface 5, 653-662 (2008).
110. G. M. Cauthen, S. W. Dooley, I. M. Onorato, W. W. Ihle, J. M. Burr, W. J. Bigler, J. Witte, K. G. Castro, Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am. J. Epidemiol. 144, 69-77 (1996).
111. R. L. Colebunders, R. W. Ryder, N. Nzilambi, K. Dikilu, J. C. Willame, M. Kaboto, N. Bagala, J. Jeugmans, K. Muepu, H. L. Francis, J. M.Mann, T. C. Quinn, P. Piot, HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am. Rev. Respir. Dis. 139, 1082-1085 (1989).
112. K. M. De Cock, E. Gnaore, G. Adjorlolo, M. M. Braun, M. F. Lafontaine, G. Yesso, G. Bretton, I. M. Coulibaly, G. M. Gershy-Damet, R. Bretton, W. L. Heyward, Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. BMJ 302, 496-499 (1991).
113. A. M. Elliott, R. J. Hayes, B. Halwiindi, N. Luo, G. Tembo, J. O. M. Pobee, P. P. Nunn, K. P. W. J. McAdam, The impact of HIV on infectiousness of pulmonary tuberculosis: A community study in Zambia. AIDS 7, 981-987 (1993).
114. W. Githui, P. Nunn, E. Juma, F. Karimi, R. Brindle, R. Kamunyi, S. Gathua, C. Gicheha, J. Morris, M. Omwega, Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: Comparison of bacteriological results. Tuber. Lung Dis. 73, 203-209 (1992).
115. P. Sonnenberg, J. Murray, S. Shearer, J. R. Glynn, B. Kambashi, P. Godfrey-Faussett, Tuberculosis treatment failure and drug resistance-Same strain or reinfection? Trans. R. Soc. Trop. Med. Hyg. 94, 603-607 (2000).